MBX Biosciences Q2 Net Loss $37.1M; R&D Up 75%
MBX Biosciences reported a net loss of $37.1 million for Q2 2026, significantly higher than $19.4 million in Q2 2025, primarily due to increased research and development and general and administrative expenses. The company successfully raised $85.0 million net from an at-the-market offering in February 2026 and subsequently increased its ATM capacity to $250.0 million. MBX maintains $418.6 million in cash, cash equivalents, and marketable securities, which management believes will fund operations for at least the next 12 months.
Key Highlights
- Net loss for Q2 2026 was $37.1 million, up from $19.4 million in Q2 2025.
- Research and development expenses increased 75% to $31.0 million in Q2 2026.
- General and administrative expenses rose to $9.9 million in Q2 2026.
- Net cash used in operating activities was $42.8 million for the six months ended June 30, 2026.
- Raised $85.0 million net from an at-the-market offering in February 2026.
- Increased at-the-market offering capacity to $250.0 million in March 2026.
- Total cash, cash equivalents, and marketable securities were $418.6 million as of June 30, 2026.
- Accumulated deficit reached $285.1 million as of June 30, 2026.
Price Impact
More from MBX
MBX Biosciences Q2 Net Loss $37.1M; Cash $418.6M; MBX 4291 Data On Track
MBX Biosciences Appoints Steven Hoerter as CEO; Kent Hawryluk Departs
MBX Biosciences Appoints Steve Hoerter as CEO, John Smither as CFO